trending Market Intelligence /marketintelligence/en/news-insights/trending/wv3velrfui9pqxg_icyhbg2 content esgSubNav
In This List

Amarin settles Vascepa patent case against Teva

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Amarin settles Vascepa patent case against Teva

Dublin-based Amarin Corp. PLC reached a settlement with Teva Pharmaceutical Industries Ltd. which is looking to sell a copycat version of the company's diet supplement Vascepa.

Amarin had filed a patent infringement lawsuit against the Israeli drug manufacturer after it sought U.S. Food and Drug Administration approval to market icosapent ethyl capsules to adults with hypertriglyceridemia, or elevated fat levels in the blood.

Under the settlement agreement, Teva may start marketing its capsules in the U.S. on Aug. 9, 2029, or earlier under certain customary circumstances. The agreement remains subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Amarin has similar Vascepa patent cases pending against West-Ward Pharmaceutical Corp., Dr. Reddy's Laboratories Inc. and their affiliates in the U.S. District Court for the District of Nevada.